1	Epigenetic Age among U.S. Adults with Chronic Respiratory Diseases: Results									
2	from NHANES 1999-2002.									
3	Research letter									
4	Running head: Epigenetic aging in chronic respiratory diseases									
5	Javier Perez-Garcia, PhD ^{1,*} , Dennis Khodasevich, PhD ¹ , Sara De Matteis, MD, MPH,									
6	PhD ² , Mary B. Rice, MD, MPH ^{3,4} , Belinda L Needham, PhD ⁵ , David H Rehkopf, ScD ^{1,6,7,8,9}									
7	Andres Cardenas, MPH, PhD ¹									
8	¹ Department of Epidemiology and Population Health, Stanford School of Medicine, Stanford									
9	University, Stanford, CA, USA.									
10	² Department of Health Sciences, University of Milan Italy.									
11	³ Division of Pulmonary and Critical Care Medicine, Department of Medicine, Beth Israel									
12	Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts, USA.									
13	⁴ Center for Climate, Health and the Global Environment, Department of Environmental Health,									
14	Harvard TH Chan School of Public Health									
15	^₅ Department of Epidemiology, University of Michigan, Ann Arbor, Michigan, USA.									
16	⁶ Department of Medicine (Division of Primary Care and Population Health), Stanford School of									
17	Medicine, Stanford University, Stanford, CA, USA.									
18	⁷ Department of Pediatrics, Stanford School of Medicine, Stanford, CA, USA.									
19	⁸ Department of Health Policy, Stanford School of Medicine, Stanford University, Stanford, CA,									
20	USA.									
21	⁹ Department of Sociology, Stanford University, Stanford, CA, USA.									
22	*Corresponding author: Javier Perez-Garcia, PhD. Department of Epidemiology and Population									
23	Health, Stanford University, Stanford, CA, USA. Email: jpegarci@stanford.edu									
24	Subject category: CELL AND MOLECULAR BIOLOGY. 3.5 Epigenetics.									
25	Word count (main text; max. 1,000): 1,067 words.									
26	Number of figures and tables (max. of two display elements): 1 Figure and 1 Table									
27	Number of references (max. 10): 10									

It is made available under a CC-BY 4.0 International license .

28 ABSTRACT

Background: Chronic airway diseases are leading causes of mortality and morbidity
worldwide. More evidence supports that lung aging can be reflected by changes in DNA
methylation, which are relevant for lung diseases, given their ability to capture exposures
over a lifetime.

33 **Objective:** We aimed to investigate the association and sex-specific associations of 34 epigenetic age acceleration in whole blood with chronic respiratory diseases.

Methods: We analyzed public data from 2,402 adults from the National Health and Nutrition Examination Surveys (NHANES) 1999-2002 cycles. We examined the association between epigenetic age and respiratory traits using linear regression models corrected for age, age², gender, race-ethnicity, survey cycles, and survey weights. Multiple comparisons were corrected using a false discovery rate <5%. We conducted stratified analyses by sex and sensitivity analyses adjusted by blood cell counts and clinical and socioeconomic status (SES) confounders.

42 **Results:** Individuals with wheezing showed accelerated epigenetic aging of up to 3.1 43 years (95% Confidence Interval [CI], 2.1, 4.1, p=8.4x10⁻⁶). Participants with COPD 44 exhibited an epigenetic age acceleration potentially mediated by smoking, while those 45 with emphysema showed epigenetic aging of up to 4.4 years (95% CI: 3.1, 5.8, $p=3.4\times10^{-1}$ 46 ⁶) independent of SES factors. Participants with early-onset COPD and those who ever 47 have asthma showed suggestive accelerated biological aging (p < 0.05). The accelerated 48 pace of biological aging in COPD participants and the telomere length reduction in 49 wheezing subjects were stronger in males than females.

It is made available under a CC-BY 4.0 International license .

50 **Conclusion:** Individuals with chronic respiratory diseases, such as wheezing, COPD, and 51 asthma, have accelerated epigenetic aging in whole blood. Among COPD patients, those 52 with emphysema might exhibit higher epigenetic age acceleration. These results suggest 53 that different epigenetic clocks may capture aging mechanisms with sex-specific effects 54 on chronic respiratory diseases.

55 Keywords: Aging, DNA methylation, Epigenetic clock, National Health and Nutrition
56 Examination Survey, Respiratory health.

57 Chronic respiratory diseases affect over 212 million people worldwide and rank as 58 the third leading cause of mortality (1). Increasing evidence indicates that aging 59 significantly contributes to their pathogenesis linked to epigenetic changes over the 60 lifespan (2,3). DNA methylation markers, which capture gene-environment factors, may 61 underly the development of respiratory diseases and can predict biological aging rates 62 (2.3). Recent findings linked accelerated epigenetic aging with poor respiratory health 63 outcomes (2,4-7), suggesting that investigating the influence of aging on chronic 64 respiratory diseases may lead to the discovery of new therapeutic strategies and help 65 target therapies (2).

This study aimed to analyze public data from the National Health and Nutrition Examination Surveys (NHANES) to investigate the overall association and sex-specific associations of epigenetic age acceleration in whole blood with chronic respiratory diseases among the U.S. adult civilian non-institutionalized population.

70 DNA methylation was measured in whole blood from adults aged \geq 50 years from the 71 1999-2000 and 2001-2002 NHANES cycles using the Infinium MethylationEPIC array 72 (Illumina). Methylation-derived blood cell counts and epigenetic clocks were estimated, 73 including chronological age clocks (HorvathAge, HannumAge, and SkinBloodAge), 74 lifespan and health span clocks (PhenoAge, GrimAgeMort, and GrimAge2Mort), pace of 75 aging (DunedinPoAm), and DNA methylation telomere length (HorvathTelo). The 76 NHANES website details sample eligibility, laboratory procedures, and bioinformatic 77 analyses (8). Demographic and respiratory health data were recorded through 78 standardized questionnaires. Informed consent was provided by all participants, and 79 ethics review boards approved study protocols.

It is made available under a CC-BY 4.0 International license .

80 After excluding individuals top coded as aged ≥85 years and participants with sex 81 mismatch, we analyzed 2,402 participants in this study. Participants had an average age 82 of 65.1±9.3 years, and 48.8% were females. Participants self-identified as Non-Hispanic 83 White (39.3%), Mexican American (29.0%), Black (21.8%), other Hispanic (6.4%), or 84 other/multi-racial race (3.5%). Among them, 323 (13.8%) reported wheezing in the past 85 vear. 196 (8.4%) had chronic obstructive respiratory disease (COPD) (147 with chronic 86 bronchitis and 68 with emphysema), and 248 (10.6%) had asthma (94 reported current 87 asthma and 66 experienced asthma exacerbations in the past year, based on the report 88 of asthma attacks and emergency room visits).

89 We examined the association between epigenetic age and respiratory traits using 90 linear regression models adjusted for age, age², gender, race-ethnicity, and survey cycles. 91 Participants without reporting any chronic respiratory trait were included as controls. 92 Models accounted for survey weights to correct for selection, non-response, and coverage 93 biases following the NHANES analytic guidelines (8). Multiple comparisons were adjusted 94 using a false discovery rate (FDR)<5%. We conducted sensitivity analyses further 95 adjusting for blood cell counts (CD8⁺ T cells, CD4⁺ T cells, NK cells, B cells, monocytes, 96 and neutrophils), and for potential clinical and socioeconomic status (SES) confounders, 97 such as smoking (never, former, and current), body mass index, education level, income, occupation, and poverty-to-income ratio. 98

We observed that individuals reporting wheezing in the past year had accelerated epigenetic aging compared to non-wheezing individuals (**Figure 1**, **Table 1**). Wheezing individuals were 3.1 years higher in GrimAge2 (95% Confidence Interval [CI], 2.1, 4.1) and 2.7 years higher in GrimAge (95% CI: 1.8, 3.6). Individuals with wheezing also

exhibited shorter average telomere length of -77.6 bp (95% CI: -118.0, -37.3). Although we observed a higher 4.2% (95% CI: 2.2, 6.2) in their pace of biological aging, this finding might be driven by potential clinical and SES confounders (p>0.05). Among wheezing subjects, we observed a suggestive yet nonsignificant average 3.5% higher (95% CI: 0.2-6.8, p=0.05, FDR=0.18) aging pace among those who had ≥12 wheezing attacks in the past year compared to those with fewer episodes.

109 Moreover, we observed that adults with COPD had a mean epigenetic age of 2.0 110 (95% CI: 1.2, 2.8; GrimAge) and 2.0 years (95% CI: 1.2, 2.9; GrimAge2) greater than 111 those without COPD, and an increase of 3.4% (95% CI: 1.3, 5.6) in the pace of aging 112 (Figure 1). Nonetheless, these associations did not remain significant after adjusting for 113 smoking, BMI, and SES (Table 1), suggesting that accelerated epigenetic aging in COPD 114 could be driven by these exposures. Notably, smoking is a primary risk factor for COPD, 115 significantly affecting DNA methylation and mortality risk (9). Among COPD patients, those 116 with early onset (before age 40) suggestively showed 2.3 years higher (95% CI: 0.5, 4.1) 117 Hannum Age than those with late onset. Our findings reinforced previous evidence linking accelerated epigenetic aging with COPD (2,4,10), in addition to identifying early onset as 118 119 a potential risk factor.

Among COPD subtypes, emphysema was associated with a mean accelerated mortality-related aging of 4.4 (95% CI: 3.1, 5.8; GrimAge2) and 4.2 years (95% CI: 2.8, 5.6; GrimAge), along with a 7.3% (95% CI: 4.5, 10.1) increase in their pace of biological aging and an average telomere reduction of -100 bp (95% CI: -163.5, -38.2) (**Figure 1**). Notably, these associations remained robust after further adjustment in sensitivity analyses except for telomere length reduction (**Table 1**). Conversely, only a suggestive

yet no significant accelerated epigenetic aging was observed in individuals with chronic
bronchitis (1.2 years GrimAge, 95% CI: 0.3, 2.0). Our results suggest that accelerated
epigenetic aging may be COPD-subtype-sensitive and pronounced in emphysema
individuals.

Regarding asthma, we observed a suggestive epigenetic age acceleration in
participants who ever had asthma (0.7 years GrimAge, 95% CI: 0.1, 1,3; 0.8 years
GrimAge2, 95% CI: 0.1, 1,6), supporting previous results observed in children with asthma
(5,7).

Finally, sex-stratified analyses revealed that the accelerated pace of biological aging in COPD and the telomere length reduction associated with wheezing were stronger in males than females (**Table 1**). These results suggest that different epigenetic clocks may capture aging mechanisms with sex-specific effects on chronic respiratory diseases. Notably, epigenetic aging has been associated with drug response in asthma in a sexspecific manner (6).

140 Our study offers insights into accelerated epigenetic aging among adults with chronic 141 respiratory disorders such as wheezing, COPD (especially those with emphysema and 142 early-onset disease), and asthma, analyzing a large representative sample of the U.S. 143 adult population with high-quality data. We employed rigorous statistical methods to 144 address survey-design biases, confounders, multiple comparisons, and sex-specific 145 effects. However, several limitations must be acknowledged. The NHANES cross-146 sectional design restricts our ability to determine the direction of causation between our 147 exposure and outcome. Although NHANES is a valuable source of health data from the 148 U.S., reliance on self-reported data may bias phenotype definition. Examining further traits

It is made available under a CC-BY 4.0 International license .

(e.g., lung function and inflammatory biomarkers) and evaluating pediatric populations
could improve our understanding of epigenetic clocks as potential biomarkers for
respiratory diseases across the lifespan.

152 ACKNOWLEDGMENTS

153 The authors thank all the participants in the NHANES 1999-2000 and 2001-2002 154 cycles, as well as all researchers and people involved in the study design, data collection,

155 data curation, sample processing, methylation data generation, and open data publication.

156 FUNDING

This work was supported by grants from the National Institute of Environmental Health Sciences (NIEHS) (R01ES031259 and P42ES004705) and the National Institute on Minority Health and Health Disparities (NIMHD) (R01MD011721) of the United States National Institutes of Health (NIH). The study funders had no role in study design, data collection, data analysis, interpretation, or report writing.

162 **COMPETING INTERESTS**

163 The authors declare they have no actual or potential competing financial interests.

164 AUTHOR CONTRIBUTIONS

JP-G and AC were involved in the conceptualization and design of the study; JP-G, DK, and AC in data curation, formal analyses, and/or data interpretation; SDM and MBR helped in the interpretation of results and manuscript writing; BLN and DHR generated the data, supervised initial biomarker calculations, and secured funding; JP-G leads the visualization and writing of the original draft; and AC was responsible for funding acquisition and project supervision. All authors were involved in the critical revision of the It is made available under a CC-BY 4.0 International license .

manuscript and have read and agreed to the published version of the manuscript. The
authors agree to be accountable for all aspects of the work, ensuring its scientific accuracy
and integrity.

174 DATA AVAILABILITY

175 Demographic data, health records, and DNA methylation epigenetic clocks 176 estimated in the analyzed participants are publicly available on the NHANES website. The 177 full summary statistic report of all association analyses supporting the main conclusions 178 this study will be openly available in the Zenodo repository (DOI: of 179 10.5281/zenodo.14549722) after the publication of the manuscript.

180 **RESEARCH IMPACT**

This study provides valuable information on accelerated epigenetic aging in subjects with chronic respiratory diseases from the nationally representative NHANES survey in the U.S. We identified for the first time accelerated epigenetic age in participants with wheezing, and validated the relationship between COPD, asthma, and epigenetic age acceleration. Our results support the hypothesis that epigenetic aging biomarkers might help guide respiratory disease management and help target interventions.

It is made available under a CC-BY 4.0 International license .

187 **REFERENCES**

191

- 1. GBD 2019 Chronic Respiratory Diseases Collaborators. Global burden of chronic
 respiratory diseases and risk factors, 1990-2019: an update from the Global Burden of
 Disease Study 2019. *EClinicalMedicine*. 2023;59:101936.

2. Hernandez Cordero AI, Leung JM. ERJ advances: epigenetic ageing and leveraging

- 192 DNA methylation in chronic respiratory diseases. *Eur Respir J.* 2024;64(5):2401257.
- 193 3. Melén E, Zar HJ, Siroux V, Shaw D, Saglani S, Koppelman GH, et al. Asthma Inception:

194 Epidemiologic Risk Factors and Natural History Across the Life Course. *Am J Respir*

- 195 *Crit Care Med*. 2024;210(6):737–54.
- 196 4. Hernández Cordero Al, Yang CX, Yang J, Horvath S, Shaipanich T, MacIsaac J, et al.
- Airway Aging and Methylation Disruptions in HIV-associated Chronic Obstructive
 Pulmonary Disease. *Am J Respir Crit Care Med*. 2022;206(2):150–60.
- 5. Peng C, Cardenas A, Rifas-Shiman SL, Hivert MF, Gold DR, Platts-Mills TA, et al.
 Epigenetic age acceleration is associated with allergy and asthma in children in Project
 Viva. *J Allergy Clin Immunol.* 2019;143(6):2263-2270.e14.
- Nwanaji-Enwerem JC, Osborne A, Cardenas A. Nasal Epigenetic Age and Systemic
 Steroid Response in Pediatric Emergency Department Asthma Patients. *Allergy*.
 2022;77(1):307–9.
- 7. Cardenas A, Sordillo JE, Rifas-Shiman SL, Chung W, Liang L, Coull BA, et al. The nasal
 methylome as a biomarker of asthma and airway inflammation in children. *Nat Commun*. 2019;10(1):3095.

It is made available under a CC-BY 4.0 International license .

208	8. Centers for Disease Control and Prevention (CDC). National Center for Health Statistics										
209	(NCHS). National Health and Nutrition Examination Survey Data. Hyattsville, MD: U.S.										
210	Department of Health and Human Services, Centers for Disease Control and										
211	Prevention. 2024 [accessed Nov 2024]. Available from:										
212	https://wwwn.cdc.gov/nchs/nhanes/Default.aspx										
213	9. Morrow JD, Make B, Regan E, Han M, Hersh CP, Tal-Singer R, et al. DNA Methylation										
214	Is Predictive of Mortality in Current and Former Smokers. <i>Am J Respir Crit Care Med</i> .										
215	2020;201(9):1099–109.										
216	10. Breen M, Nwanaji-Enwerem JC, Karrasch S, Flexeder C, Schulz H, Waldenberger										
217	M, et al. Accelerated epigenetic aging as a risk factor for chronic obstructive pulmonary										

disease and decreased lung function in two prospective cohort studies. Aging.

219 2020;12(16):16539–54.

220

221 **TABLES**

		y analyses		Stratified analyses by sex							
	Clinical and SES va	ariables	Blood cell co	unts	Males		Females				
Epigenetic clock	Estimate (95% CI)	<i>p</i> -value	Estimate (95% CI)	<i>p</i> -value	Estimate (95% CI)	<i>p</i> -value	Estimate (95% CI)	<i>p</i> -value			
GrimAge2	0.77 (0.20, 1.34)	0.027	2.19 (1.54, 2.84)	1.23x10⁻⁵	2.48 (1.64, 3.32)	9.55x10⁻ ⁶	1.94 (0.89, 2.98)	0.002			
GrimAge	0.65 (0.17, 1.14)	0.027	1.91 (1.31, 2.52)	2.15x10⁻⁵	2.11 (1.33, 2.89)	2.78x10 ⁻⁵	1.73 (0.77, 2.68)	0.002			
DunedinPoAm	0.01 (-0.01, 0.02)	0.261	0.03 (0.02, 0.04)	2.44x10 ⁻⁴	0.03 (0.01, 0.04)	0.001	0.03 (0.01, 0.05)	0.012			
HorvathTelo	-0.03 (-0.06, -0.005)	0.046	-0.06 (-0.08, -0.03)	0.001	-0.09 (-0.13, -0.06)	9.91x10 ⁻⁵	-0.03 (-0.06, 0.004)	0.100			
HannumAge	0.33 (-0.22, 0.87)	0.268	0.65 (0.17, 1.13)	0.019	0.48 (-0.20, 1.16)	0.180	0.79 (-0.12, 1.70)	0.104			
PhenoAge	0.21 (-0.59, 1.01)	0.625	0.89 (0.12, 1.67)	0.041	1.01 (0.05, 1.97)	0.052	0.82 (-0.25, 1.89)	0.148			
			(COPD							
GrimAge	0.53 (-0.23, 1.30)	0.206	1.62 (0.77, 2.47)	0.002	2.38 (1.1, 3.66)	0.002	1.29 (0.06, 2.52)	0.052			
GrimAge2	0.51 (-0.23, 1.24)	0.209	1.63 (0.79, 2.48)	0.002	2.62 (1.27, 3.97)	0.001	1.21 (-0.06, 2.47)	0.076			
HannumAge	1.10 (0.21, 1.98)	0.038	1.08 (0.44, 1.72)	0.005	0.94 (-0.52, 2.4)	0.220	1.15 (0.12, 2.17)	0.039			
DunedinPoAm	0.01 (-0.01, 0.03)	0.236	0.03 (0.01, 0.05)	0.007	0.05 (0.01, 0.08)	0.014	0.02 (-0.01, 0.05)	0.135			
HorvathTelo	-0.01 (-0.05, 0.03)	0.569	-0.03 (-0.06, 0.003)	0.098	-0.06 (-0.14, 0.01)	0.100	-0.02 (-0.07, 0.02)	0.264			
COPD age onset (early than 40 years)											
HannumAge	0.68 (-1.39, 2.75)	0.535	2.72 (0.68, 4.76)	0.019							
Emphysema											
GrimAge2	GrimAge2 1.21 (0.37, 2.06) 0.020 2.41 (1.44, 3.37) 2.37x10 ⁻⁴					3.85x10⁻⁵	2.78 (1.51, 4.06)	3.36x10 ⁻⁴			
GrimAge	1.19 (0.26, 2.11)	0.033	2.37 (1.40, 3.35)	2.97x10 ⁻⁴	2.56 (1.44, 3.67)	1.98x10 ⁻⁴	2.84 (1.55, 4.12)	2.98x10 ⁻⁴			
DunedinPoAm	0.02 (0.004, 0.04)	0.040	0.04 (0.02, 0.06)	0.001	0.06 (0.03, 0.08)	2.87x10 ⁻⁴	0.05 (0.02, 0.07)	0.001			
HorvathTelo -0.02 (-0.07, 0.03) 0.397 -0.05 (-0.09, -0.01) 0.020		0.020	-0.08 (-0.14, -0.02)	0.012	-0.05 (-0.10, -0.01)	0.034					

Table 1. Sensitivity and sex-stratified analyses of the statistically significant associations between epigenetic aging biomarkers and respiratory health traits.

Only nominal associations between epigenetic clocks and respiratory traits in the main model (p<0.05) are represented in this table. Main models were adjusted for age, age², gender, race-ethnicity, and survey cycle, and corrected by survey weights. Sensitivity analyses included main covariates in addition to the specific confounders. Clinical and socioeconomic status confounders included body mass index, smoking, education level, occupation, income, and poverty-to-income ratio. Blood cell counts were estimated from DNA methylation data. Significant *p*-values are highlighted in boldface. **Abbreviations:** 95% CI: 95% confidence interval, COPD: chronic obstructive pulmonary disease, SES: socioeconomic status.

223 FIGURES

Epigenetic clock	Respiratory trait								Estimate (95% CI)	<i>p</i> -value
GrimAge2Mort	Asthma ever					⊢ •−-1			0.8 (0.1, 1.6)	0.04
	COPD					⊢ —●			2.0 (1.2, 2.9)	1.8x10 ^{-4*}
	Emphysema							•	→ 4.4 (3.1, 5.8)	3.4x10 ^{-6*}
	Wheezing								3.1 (2.1, 4.1)	8.4x10 ^{-6*}
GrimAgeMort	Asthma ever					⊢ •−-1			0.7 (0.1, 1.3)	0.03
	Chronic bronchitis					⊢			1.2 (0.3, 2.0)	0.01
	COPD					⊢ ●			2.0 (1.2, 2.8)	1.3x10 ^{-4*}
	Emphysema						⊢		4.2 (2.8, 5.6)	8.1x10 ^{-6*}
	Wheezing						• •		2.7 (1.8, 3.6)	1.2x10 ^{-5*}
HannumAge	COPD					⊢			1.2 (0.3, 2.0)	0.02
	COPD age onset (<40 yo)					• — •			2.3 (0.5, 4.1)	0.02
	Wheezing					⊢			0.9 (0.2, 1.7)	0.03
PhenoAge	Wheezing						1		1.3 (0.2, 2.5)	0.04
			-4	-2	C) 2	4			
DunedinPoAm	COPD					⊢ •−−1			0.03 (0.01, 0.06)	0.006*
	Emphysema					⊢ →			0.07 (0.05, 0.10)	5.2x10 ^{-5*}
	Wheezing					⊢ •−-1			0.04 (0.02, 0.06)	0.001*
HorvathTelo	COPD		F	•	-				-0.05 (-0.08, -0.01)	0.02
	Emphysema		•						-0.10 (-0.16, -0.04)	0.005*
	Wheezing	-0.15	-0.1	-0.05	(0.05	0.1	0.15	-0.08 (-0.1, -0.04)	0.005*

224

Figure 1. Forest plot displaying the estimates and 95% confidence intervals of the associations between epigenetic aging biomarkers and chronic respiratory diseases. Only nominal associations (p<0.05) are represented, and those significant after multiple comparison adjustments using a false discovery rate (FDR) <5% are marked with an asterisk. Positive estimates indicate accelerated epigenetic aging, except for HorvathTelo, since shorter telomere lengths indicate accelerated aging. The vertical dashed line at zero represents no association. Abbreviations. 95% CI: 95% confidence interval, COPD: chronic respiratory disease.

Epigenetic clock	Respiratory trait								Estimate (95% CI)	<i>p</i> -value
GrimAge2Mort	Asthma ever				ļ				0.8 (0.1, 1.6)	0.04
	COPD				ł	⊢ ●			2.0 (1.2, 2.9)	1.8x10 ^{-4*}
	Emphysema				i			•	⊣ 4.4 (3.1, 5.8)	3.4x10 ^{-6*}
	Wheezing				i				3.1 (2.1, 4.1)	8.4x10 ^{-6*}
GrimAgeMort	Asthma ever				ļ				0.7 (0.1, 1.3)	0.03
	Chronic bronchitis				1	⊢			1.2 (0.3, 2.0)	0.01
	COPD					⊢ ●			2.0 (1.2, 2.8)	1.3x10 ^{-4*}
	Emphysema						•		4.2 (2.8, 5.6)	8.1x10 ^{-6*}
	Wheezing						•		2.7 (1.8, 3.6)	1.2x10 ^{-5*}
HannumAge	COPD				į	⊢			1.2 (0.3, 2.0)	0.02
	COPD age onset (<40 yo)				i	••			2.3 (0.5, 4.1)	0.02
	Wheezing					⊢ 1			0.9 (0.2, 1.7)	0.03
PhenoAge	Wheezing				1	⊢	1		1.3 (0.2, 2.5)	0.04
		-	4	-2	0	2	4			
DunedinPoAm	COPD					⊢			0.03 (0.01, 0.06)	0.006*
	Emphysema					⊢ —●			0.07 (0.05, 0.10)	5.2x10 ^{-5*}
	Wheezing					⊢_ •1			0.04 (0.02, 0.06)	0.001*
HorvathTelo	COPD		F	•	— į				-0.05 (-0.08, -0.01)	0.02
	Emphysema		•		i				-0.10 (-0.16, -0.04)	0.005*
	Wheezing	-0.15	-0.1	-0.05	0	0.05	0.1	0.15	-0.08 (-0.1, -0.04)	0.005*